Stem Cells
Therapies

Stem Cells Therapies

The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).

FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.

Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.

Check the full list of patients who received stem cell therapy derived from FamiCord labs.

List last update: 06.2026

List of patients who received stem cells from FamiCord Group laboratories

List of patients who received stem cells from FamiCord Group laboratories
Lp.	Source	Source type	Diagnosis	Medical field	Year of application	Therapy	Country	Age of recipient
401	Apheresis	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Canada	26
402	Apheresis	Allogeneic	Hodgkin Lymphoma	Hematology	2026	Standard Therapy	Poland	40
403	Apheresis	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Netherlands	68
404	Apheresis	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	United Kingdom	56
405	Apheresis	Allogeneic	Myelodysplastic/Myeloproliferative Neoplasms	Hematology	2026	Standard Therapy	Spain	65
406	Apheresis	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Germany	63
407	Apheresis	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Germany	58
408	Apheresis	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Poland	44
409	Apheresis	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Czechia	61
410	Apheresis	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Australia	54
411	Apheresis	Allogeneic	Severe Aplastic Anemia	Hematology	2026	Standard Therapy	Poland	11
412	Apheresis	Allogeneic	Chronic Myeloid Leukemia	Hematology	2026	Standard Therapy	USA	64
413	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Portugal	64
414	Apheresis	autologous	Hodgkin Lymphoma	Hematology	2026	Standard Therapy	Germany	32
415	Apheresis	autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	69
416	Apheresis	allogeneic	Acute Myeloid Leukemia	Hematology	2026	Standard Therapy	Germany	54
417	Apheresis	autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	64
418	Apheresis	autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	72
419	Apheresis	autologous	Peripheral T-cell Lymphoma	Hematology	2026	Standard Therapy	Germany	56
420	Apheresis	autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	60
421	Apheresis	autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	61
422	Apheresis	autologous	Anaplastic Large-Cell Lymphoma	Hematology	2026	Standard Therapy	Germany	47
423	Apheresis	autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	60
424	Apheresis	allogeneic	Vexas-Syndrome with UBA1-Mutation	Hematology	2026	Standard Therapy	Germany	67
425	Apheresis	allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	USA	27
426	Apheresis	allogeneic	Primary Myelofibrosis PMF	Hematology	2026	Standard Therapy	Poland	57
427	Apheresis	allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Poland	48
428	Apheresis	allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Switzerland	67
429	Apheresis	allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Germany	42
430	Apheresis	allogeneic	MPS-I: Hurler Syndrome	Hematology	2026	Standard Therapy	Russia	1
431	Apheresis	allogeneic	Acute Lymphoblastic Leukemia	Hematology	2026	Standard Therapy	USA	29
432	Apheresis	allogeneic	Acute Lymphoblastic Leukemia	Hematology	2026	Standard Therapy	USA	47
433	Apheresis	allogeneic	Non-Hodgkin Lymphoma	Hematology	2026	Standard Therapy	USA	66
434	Apheresis	allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Poland	4
435	Apheresis	allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	USA	68
436	Apheresis	allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	USA	63
437	Apheresis	allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	Lithuania	40
438	Apheresis	allogeneic	Non-Hodgkin Lymphoma	Hematology	2026	Standard Therapy	Germany	68
439	Apheresis	allogeneic	Chronic Lymphocytic Leukemia	Hematology	2026	Standard Therapy	Netherlands	61
440	Apheresis	allogeneic	Acute Lymphoblastic leukemia	Hematology	2026	Standard Therapy	Germany	21
441	Apheresis	allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	USA	72
442	Apheresis	allogeneic	Non-Hodgkin Lymphoma	Hematology	2026	Standard Therapy	USA	36
443	Apheresis	allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Germany	57
444	Apheresis	allogeneic	Acute Lymphoblastic Leukemia	Hematology	2026	Standard Therapy	Belgium	63
445	Apheresis	allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	United Kingdom	54
446	Apheresis	allogeneic	Other Malignancy, Specify	Hematology	2026	Standard Therapy	USA	54
447	Apheresis	allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	USA	76
448	Apheresis	allogeneic	Myelodysplastic Disorders	Hematology	2026	Standard Therapy	France	73
449	Apheresis	allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	Germany	75
450	Apheresis	allogeneic	Hodgkin Lymphoma	Hematology	2026	Standard Therapy	Poland	47
451	Apheresis	allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	USA	68
452	Apheresis	allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Italy	40
453	Apheresis	allogeneic	Acute Myeloid Leukemia	Hematology	2026	Standard Therapy	Macedonia	59
454	Apheresis	allogeneic	Combined Immunodeficiency	Hematology	2026	Standard Therapy	Belgium	4
455	Apheresis	allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	Australia	13
456	Apheresis	allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Poland	33
457	Apheresis	allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	Italy	38
458	Apheresis	allogeneic	Acute Lymphoblastic Leukemia	Hematology	2026	Standard Therapy	Russian Federation	28
459	Apheresis	allogeneic	Severe Aplastic Anemia	Hematology	2026	Standard Therapy	Germany	58
460	Apheresis	allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Austria	54
461	Apheresis	allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	USA	74
462	Apheresis	allogeneic	Acute Lymphoblastic Leukemia	Hematology	2026	Standard Therapy	United Kingdom	20
463	Apheresis	allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	USA	57
464	Apheresis	allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	Germany	69
465	Apheresis	allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Spain	64
466	Apheresis	allogeneic	Myelodysplastic Syndrome	Hematology	2026	Standard Therapy	Germany	56
467	Apheresis	autologous	Myeloma	Hematology	2026	Standard Therapy	Portugal	42
468	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	56
469	Apheresis	Autologous	T-Cell Lymphoma	Hematology	2026	Standard Therapy	Germany	68
470	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	71
471	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	61
472	Apheresis	Allogeneic	T-Cell Acute Lymphoblastic Leukemia	Hematology	2026	Standard Therapy	Germany	24
473	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	67
474	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	62
475	Apheresis	Autologous	Plasma Cell Leukemia	Hematology	2026	Standard Therapy	Germany	43
476	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2026	Standard Therapy	Germany	60
477	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	68
478	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	68
479	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	70
480	Apheresis	Allogeneic	Primary Myelopathic Polycythemia	Hematology	2026	Standard Therapy	Germany	67
481	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	61
482	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	56
483	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Germany	69
484	Apheresis	Autologous	Multiple Myeloma	Hematology	2026	Standard Therapy	Portugal	32
485	Apheresis	Autologous	Lymphoma	Hematology	2026	Standard Therapy	Portugal	64
486	Apheresis	Autologous	Lymphoma	Hematology	2026	Standard Therapy	Portugal	64
487	Apheresis	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Poland	42
488	Apheresis	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Poland	65
489	Apheresis	Allogeneic	Chronic myelomonocytic leukemia	Hematology	2026	Standard Therapy	Germany	73
490	Apheresis	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Spain	63
491	Apheresis	Allogeneic	Thalassemia Major	Hematology	2026	Standard Therapy	Italy	6
492	Apheresis	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	USA	63
493	Apheresis	Allogeneic	Hemophagocytic Lymphohistiocytosis	Hematology	2026	Standard Therapy	India	3
494	Apheresis	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Bulgaria	32
495	Apheresis	Allogeneic	Mixed-Phenotype Acute Leukemia	Hematology	2026	Standard Therapy	Poland	40
496	Apheresis	Allogeneic	Chronic Myelomonocytic Leukemia	Hematology	2026	Standard Therapy	USA	64
497	Apheresis	Allogeneic	Acute Lymphoblastic Leukemia	Hematology	2026	Standard Therapy	Ukraine	58
498	Apheresis	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	Poland	62
499	Apheresis	Allogeneic	Acute Myelogenous Leukemia	Hematology	2026	Standard Therapy	France	45
500	Apheresis	Allogeneic	T-cell non-Hodgkin Lymphoma (Mycosis Fungoides)	Hematology	2026	Standard Therapy	Portugal	43

Page 5 from 89 1 3 4 5 6 7 89